Claret Asset Management Corp Sells 24,545 Shares of Pfizer Inc. $PFE

Claret Asset Management Corp lessened its holdings in Pfizer Inc. (NYSE:PFE) by 8.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 283,977 shares of the biopharmaceutical company’s stock after selling 24,545 shares during the quarter. Claret Asset Management Corp’s holdings in Pfizer were worth $7,236,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in PFE. Grey Fox Wealth Advisors LLC acquired a new position in Pfizer in the 3rd quarter valued at approximately $29,000. Howard Hughes Medical Institute acquired a new position in shares of Pfizer during the second quarter worth $30,000. Darwin Wealth Management LLC acquired a new position in shares of Pfizer during the second quarter worth $32,000. Evelyn Partners Asset Management Ltd bought a new stake in shares of Pfizer in the second quarter worth $33,000. Finally, True Wealth Design LLC increased its holdings in Pfizer by 302.5% in the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 974 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have commented on the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. Barclays started coverage on Pfizer in a research note on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price target for the company. Scotiabank assumed coverage on Pfizer in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price objective on the stock. Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price on the stock. in a report on Thursday, February 12th. Finally, Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price for the company in a research report on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.05.

Pfizer Stock Performance

Shares of Pfizer stock opened at $26.81 on Tuesday. The business has a 50-day moving average price of $26.34 and a two-hundred day moving average price of $25.48. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.94. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The company has a market cap of $152.42 billion, a P/E ratio of 19.71 and a beta of 0.47.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same period in the previous year, the business earned $0.63 EPS. The firm’s revenue was down 1.2% compared to the same quarter last year. As a group, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, March 6th. Shareholders of record on Friday, January 23rd were paid a $0.43 dividend. The ex-dividend date of this dividend was Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.4%. Pfizer’s payout ratio is 126.47%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.